Shares of both Ultragenyx and Mereo BioPharma were seeing record selloffs after disappointing trial results for setrusumab.

Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts ...

O4, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

The bank's list of highest-conviction stock picks for 2026 spans numerous sectors and features names including Pepsi and GM.

Sanofi has agreed to acquire vaccine maker Dynavax Technologies in an all-cash deal worth $2.2 billion in total equity value.

The stock has lost significant market value since that debacle. While it's not clear that nex-z was responsible, it's also ...

Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro ...

This stock is a great choice for cautious and aggressive investors.

Abivax (ABVX) stock leads biotech M&A prospects for 2026 while Madrigal Pharmaceuticals (MDGL) trails, according to a survey ...

An investor whose portfolio contains some value- or income-focused investments and some growth-oriented investments, who ...